Octave Specialty Group, Inc.

NYSE:OSG Lagerbericht

Marktkapitalisierung: US$258.4m

Octave Specialty Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Für Octave Specialty Group wird ein Gewinn- und Umsatzwachstum von 71.8% bzw. 18.1% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 71.4% pro Jahr steigen soll.

Wichtige Informationen

71.8%

Wachstumsrate der Gewinne

71.37%

EPS-Wachstumsrate

Insurance Gewinnwachstum2.0%
Wachstumsrate der Einnahmen18.1%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert07 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrativ-Update • May 13

OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential

Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.
Narrativ-Update • Apr 22

OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential

Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).
Narrativ-Update • Apr 07

OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential

Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).
Narrativ-Update • Mar 23

OSG: Share Repurchases Will Support Future Upside Potential

Analysts now hold their price target for Octave Specialty Group at $12.00, reflecting slightly updated assumptions for revenue growth, profit margins, discount rate, and future P/E that fine tune rather than overhaul their prior view. What's in the News Completed share repurchase program with a total of 4,371,886 shares bought back for $42.45 million, representing 9.33% of shares under the buyback announced on November 12, 2024 (Key Developments).
Narrativ-Update • Mar 09

OSG: Share Repurchases And Auditor Shift Will Support Future Upside Potential

Analysts have reduced their price target on Octave Specialty Group from $15.00 to $12.00, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Completed share repurchase of 4,371,886 shares in total, representing 9.33% of shares, for $41.69 million under the buyback announced on November 12, 2024.
Narrativ-Update • Feb 22

OSG: Auditor Transition And Execution Will Support Future Upside Potential

Analysts have adjusted their price target on Octave Specialty Group to $15.00. This change reflects updated assumptions around slightly higher projected revenue growth, a modestly stronger profit margin, and a lower future P/E multiple.
Narrativ-Update • Feb 07

OSG: ArmadaCare Execution And Organic Expansion Will Support Future Upside Potential

Analysts have raised their price target on Octave Specialty Group to $15 from $10, citing updated models that incorporate recent earnings, higher assumed organic growth, and the impact of the ArmadaCare deal. Analyst Commentary While the new US$15 price target signals higher modeled value for Octave Specialty Group, not all of the commentary behind the scenes is purely optimistic.
Narrativ-Update • Jan 24

OSG: Higher Growth Assumptions And ArmadaCare Integration Will Drive Future Upside

Narrative Update Analysts have lifted their price target on Octave Specialty Group to US$15 from US$10, citing refreshed models that factor in higher assumed organic growth, the ArmadaCare acquisition and recent quarterly performance. Analyst Commentary While the higher US$15 target reflects more constructive modeling around organic growth and the ArmadaCare acquisition, not all commentary skews optimistic.
Narrativ-Update • Jan 09

OSG: Earnings Beat And ArmadaCare Integration Will Support Long-Term Share Gains

Analysts have raised their price target on Octave Specialty Group by $5 to $15, citing updated models that incorporate Q3 earnings, revised assumptions for organic growth, and the expected impact of the ArmadaCare transaction. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated Q3 earnings model as support for the new US$15 price target, arguing that current valuation better reflects Octave Specialty Group's recent financial results.
Narrativ-Update • Dec 25

OSG: Earnings Beat And Deals Will Drive Long-Term Shareholder Upside

Analysts raised their price target for Octave Specialty Group by $5, increasing it to $15 from $10. They cited updated models that reflect stronger assumed organic growth following an earnings beat and recent strategic transactions, which they believe support a path to sustained elevated expansion.
Narrativ-Update • Dec 11

OSG: Q3 Earnings Beat Will Support Long-Term Shareholder Value Expansion

Analysts raised their price target on Octave Specialty Group to $15 from $10, citing updated models that reflect stronger than expected Q3 performance, higher assumed organic growth, and incremental upside from recent strategic deals. Analyst Commentary Analysts note that the revised price target for Octave Specialty Group is grounded in tangible improvements to the company’s growth profile, as well as rising confidence in management’s ability to execute on recent strategic initiatives.
Narrativ-Update • Nov 27

OSG: Sustained Organic Expansion Will Drive Long-Term Shareholder Value

Analysts have raised their price target for Octave Specialty Group, increasing it by $5 to reflect stronger than expected organic growth and recent strategic acquisitions. Analyst Commentary Following the recent price target increase, analysts have provided additional context regarding their views on Octave Specialty Group's prospects.
Narrativ-Update • Nov 13

AMBC: Revenue Momentum and Armada Acquisition Will Drive Further Share Upside

Analysts have raised their price target for Octave Specialty Group from $14.67 to $16.33. They cite stronger projected revenue growth and improved profitability metrics in their updated outlook.
Seeking Alpha • Oct 03

Ambac: Surprise Acquisition Changes Outlook (Rating Downgrade)

Summary Ambac is downgraded to Hold following the surprise $250M ArmadaCare acquisition after selling its legacy guarantee business. The new deal adds product diversification and potential growth, but reintroduces debt and increases risk to the balance sheet. Management maintains 2028 adjusted EBITDA guidance at $80M–$90M, despite the significant size of the ArmadaCare acquisition. I recommend waiting for a lower entry price below $7 or more clarity in Q3 results before considering AMBC a Buy again. Read the full article on Seeking Alpha
User avatar
Neues Narrativ • Jul 20

US Infrastructure Spending And Automation Will Unlock Insurance Potential

Diversification into specialty insurance and tech-driven operations is improving revenue stability, earnings quality, and operational efficiency.
Seeking Alpha • Mar 01

Ambac: Despite EPS Miss, It's A Growth Company

Summary Ambac Financial Group saw a stock decline after an earnings miss for Q4. Such a sell-off overlooks the fundamental improvements: profitable underwriting and the build-out of a higher-ROE distribution platform. The sale of the legacy business remains to be approved by Wisconsin, creating a thorn in AMBC's side for the moment. Management, however, was eager about the growth ahead; the current price is a small P/E for earnings in just a few years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 27

Ambac Financial: Don't Get Lost In The Weeds; It's Working

Summary Ambac Financial Group has shifted from guarantee insurance to specialty property-casualty insurance and distribution. Despite a drop in tangible book value per share, the sale of the legacy business and recent acquisitions are expected to improve financials and boost earnings. Ambac Financial faces risks from recent hurricanes and potential delays in the legacy business sale approval, but overall outlook remains positive. I maintain a Buy rating on AMBC stock, believing Ambac's turnaround strategy will lead to better capitalization and improved earnings, offering a favorable risk-reward asymmetry. Read the full article on Seeking Alpha
Seeking Alpha • Jul 30

Ambac Financial: Unbundling The Recent Sale And The New Acquisition

Summary Ambac sold its Financial Guarantee business to Oaktree at a disappointing valuation, causing a 20% drop in stock price. The company reinvested proceeds into acquiring a majority stake in Beat Capital Partners for $280 million at a generous valuation, raising concerns among investors. Despite the negative stock reaction, a new valuation framework suggests a fair value per share of around $15, indicating a 20% upside potential. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

Ambac: Finally Shaking Off The Great Financial Crisis

Summary Ambac Financial Group has undergone a turnaround after the 2008 Financial Crisis, improving its financial position and evolving its business model. The company's balance sheet appears healthy and able to meet upcoming obligations, with a new focus on specialty property-casualty insurance. AMBC is positioning itself to underwrite its products through a technology-driven MGA model, aiming to take advantage of the growing US market with attractive loss ratios. Yet, investors should remember that the discount exists for a reason, given how a recession could particularly affect a company like this. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Ambac: Releasable Liquidity And SOTP Analysis Reveals Upside Potential

Summary Ambac is a complex company with a financial guarantees business and a new specialty P&C insurance business. We run a comparison with MBIA to compute releasable liquidity from the FG business that may be paid out as a special dividend. Ambac may benefit from a liquidity release or a sale, but the bulk of its value lies in its new businesses. Read the full article on Seeking Alpha
Seeking Alpha • Sep 24

Ambac Financial Group Inc: Debt Trap Disguised As Value Opportunity

Summary Ambac Financial Group Inc is trading at low multiples but has a significant amount of debt that is impacting its expansion capacities. AMBC operates through two divisions, Everspan and Cirrata, and presents itself as an opportunity in the growing specialty coverage market. The company's high debt levels and inconsistent bottom line make it a risky investment, and the share price is expected to decline further. Read the full article on Seeking Alpha
Seeking Alpha • Jun 14

Ambac Remains Discounted By An Apprehensive Market

Summary Ambac has seen significant price appreciation since the announced settlement with Bank of America and Nomura Holdings. Alongside aggressive growth from Cirrata, shareholders can expect effective organic and inorganic growth from Ambac. Despite these factors, Ambac still trades at a 23% undervaluation, leading me to rate the company a 'buy'. Read the full article on Seeking Alpha
Seeking Alpha • Jan 03

Ambac settles with Nomura, closing financial crisis-era RMBS lawsuits

Ambac Financial Group (NYSE:AMBC) said Tuesday its Assurance Corporation subsidiary (AAC) entered into a settlement agreement with Nomura (NYSE:NMR) that will give AAC $140M. The settlement brings to an end all of Ambac's (AMBC) legacy residential mortgage-backed securities representation and warranty litigation that arose from the 2008 financial crisis. In October, Bank of America (BAC) agreed to pay Ambac $1.8B to settle litigation related to mortgage company Countrywide's collapse during the crisis. The settlement exceeds the amount of recovery recorded on Ambac's (AMBC) Q3 2022 GAAP financial statements attributed to the Nomura (NMR) litigation. As a result, the company will record a gain of ~$43M in its Q4 financial statement. Last month, Street Insider reported that Assured Guaranty (AGO) and Ambac Financial (AMBC) had made bids for rival MBIA (MBI).
Analyseartikel • May 12

Just In: One Analyst Has Become A Lot More Bullish On Ambac Financial Group, Inc.'s (NYSE:AMBC) Earnings

Celebrations may be in order for Ambac Financial Group, Inc. ( NYSE:AMBC ) shareholders, with the covering analyst...

Gewinn- und Umsatzwachstumsprognosen

NYSE:OSG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2027408-25N/AN/A1
12/31/2026369-45N/AN/A1
3/31/2026293-96-50-50N/A
12/31/2025251-117-52-52N/A
9/30/2025254-106-171-171N/A
6/30/2025258-94-50-50N/A
3/31/2025254-87-29-29N/A
12/31/2024241-6511N/A
9/30/2024105-7811N/A
6/30/20241048-32-32N/A
3/31/202411310-23-23N/A
12/31/2023125-203737N/A
9/30/20233251971,3881,388N/A
6/30/20233204711,4251,425N/A
3/31/20232734891,4031,403N/A
12/31/202254-337070N/A
9/30/20222343276464N/A
6/30/20222164-37-37N/A
3/31/2022258-31-82-82N/A
12/31/2021249-29-131-131N/A
9/30/2021245-23-144-144N/A
6/30/2021254-148-146-146N/A
3/31/2021275-153-128-128N/A
12/31/2020156-437-175-175N/A
9/30/2020175-533-182-182N/A
6/30/2020195-359-158-158N/A
3/31/2020217-453-303-303N/A
12/31/2019362-216N/A-311N/A
9/30/2019337-126N/A-421N/A
6/30/2019393-296N/A-496N/A
3/31/2019444-163N/A-446N/A
12/31/2018506186N/A-1,543N/A
9/30/2018629187N/A-1,394N/A
6/30/2018629100N/A-1,367N/A
3/31/2018613102N/A-1,408N/A
12/31/2017567-329N/A-221N/A
9/30/2017551-404N/A-227N/A
6/30/2017577-112N/A-196N/A
3/31/2017576-60N/A11N/A
12/31/201655275N/A830N/A
9/30/2016542557N/A835N/A
6/30/201653264N/A927N/A
3/31/2016584288N/A914N/A
12/31/2015688493N/A92N/A
9/30/2015662560N/A-1,148N/A
6/30/20156851,033N/A-1,105N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OSG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OSG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OSG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OSGDie Einnahmen des Unternehmens (18.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: OSGDie Einnahmen des Unternehmens (18.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OSG in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 16:41
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Octave Specialty Group, Inc. wird von 7 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Giuliano Anderes BolognaBTIG
Mary KaneCitigroup Inc
Giuliano Anderes BolognaCompass Point Research & Trading, LLC